Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Transplant for High Risk Hemoglobinopathy
NCT00176852Phase 3Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2002
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of alemtuzumab in sickle cell disease (SCD), thalassemia, severe congenital neutropenia (SCN) and 2 more (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity at 1 year. Started Jun 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
sickle cell disease (SCD)thalassemiasevere congenital neutropenia (SCN)Diamond-Blackfan anemia (DBA)Shwachman-Diamond syndrome (SDS)
Beyond the preview
Go deeper on NCT00176852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176852.